Your browser doesn't support javascript.
loading
RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.
Bockorny, Bruno; Rusan, Maria; Chen, Wankun; Liao, Rachel G; Li, Yvonne; Piccioni, Federica; Wang, Jun; Tan, Li; Thorner, Aaron R; Li, Tianxia; Zhang, Yanxi; Miao, Changhong; Ovesen, Therese; Shapiro, Geoffrey I; Kwiatkowski, David J; Gray, Nathanael S; Meyerson, Matthew; Hammerman, Peter S; Bass, Adam J.
  • Bockorny B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rusan M; Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Chen W; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Liao RG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li Y; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Piccioni F; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Wang J; Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Tan L; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Thorner AR; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Li T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhang Y; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Miao C; Genetic Perturbation Platform, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Ovesen T; Department of Integrative Medicine and Neurobiology, Institutes of Brain Science, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
  • Shapiro GI; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, Shanghai, China.
  • Kwiatkowski DJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gray NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Meyerson M; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hammerman PS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mol Cancer Ther ; 17(7): 1526-1539, 2018 07.
Article en En | MEDLINE | ID: mdl-29654068
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos / Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos / Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2018 Tipo del documento: Article